Molecular studies show that despite low tumor mutational burden (TMB), responders exhibit higher chromosomal instability (CIN), TP53 mutations, and enrichment of proliferative and cell-cycle signatures, associated with higher density of Ki-67<sup>+</sup> tumor and CD8<sup>+</sup> T cells. The gene discussed is MKI67; the disease is neoplasm.